Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone610-254-4201
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable
Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions
What is Aevi Genomic Medicine's stock symbol?
Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."
How were Aevi Genomic Medicine's earnings last quarter?
Aevi Genomic Medicine Inc (NASDAQ:GNMX) announced its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History.
When is Aevi Genomic Medicine's next earnings date?
What is the consensus analysts' recommendation for Aevi Genomic Medicine?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aevi Genomic Medicine in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aevi Genomic Medicine.
Has Aevi Genomic Medicine been receiving favorable news coverage?
Headlines about GNMX stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aevi Genomic Medicine earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Aevi Genomic Medicine's key competitors?
Some companies that are related to Aevi Genomic Medicine include BioCardia (BCDA), Pharmacyte Biotech (PMCB), Entera Bio (ENTX), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), Titan Pharmaceuticals (TTNP), TRACON Pharmaceuticals (TCON), aTyr Pharma (LIFE), CytRx (CYTR), Outlook Therapeutics (OTLK), Windtree Therapeutics (WINT), TrovaGene (TROV), Genetic Technologies (GENE) and Enzon Pharmaceuticals (ENZN).
What other stocks do shareholders of Aevi Genomic Medicine own?
Who are Aevi Genomic Medicine's key executives?
Aevi Genomic Medicine's management team includes the folowing people:
- Mr. Michael F. Cola, CEO, Pres & Director (Age 59)
- Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)
- Dr. Garry A. Neil, Chief Scientific Officer (Age 65)
Who are Aevi Genomic Medicine's major shareholders?
Aevi Genomic Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.43%). Company insiders that own Aevi Genomic Medicine stock include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine.
Which institutional investors are buying Aevi Genomic Medicine stock?
GNMX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine.
How do I buy shares of Aevi Genomic Medicine?
Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aevi Genomic Medicine's stock price today?
One share of GNMX stock can currently be purchased for approximately $0.2201.
How big of a company is Aevi Genomic Medicine?
Aevi Genomic Medicine has a market capitalization of $14.26 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 14 workers across the globe.
What is Aevi Genomic Medicine's official website?
How can I contact Aevi Genomic Medicine?
Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]
MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
